Table1_Efficacy of polyethylene glycol loxenatide for type 2 diabetes mellitus patients: a systematic review and meta-analysis.DOC

Objective: Some studies have proved that polyethylene glycol loxenatide (PEG-Loxe) has significant effects on controlling blood glucose and body weight in patients with type 2 diabetes mellitus (T2DM), but there is still some controversy over the improvement of blood lipid profiles (BLP) and blood pressure (BP), and more evidences are needed to verify such effects. Therefore, this study was conducted to provide a comprehensive evaluation of the efficacy of PEG-Loxe in improving blood glucose (BG), BLP, BP, body mass index (BMI), and body weight (BW) in patients with T2DM for clinical reference.
Methods: Randomized controlled trials (RCT) in which PEG-Loxe was applied to treat T2DM were retrieved by searching PubMed, Cochrane Library, Embase, Medline, Scopus, Web of Science, China National Knowledge Infrastructure, China Scientific Journal, Wanfang Data, and SinoMed databases. Outcome measures included BG, BLP, BP, BMI, and BW. RevMan 5.3 software was used to perform data analysis.
Results: Eighteen trials were identified involving 2,166 patients. In experimental group 1,260 patients received PEG-Loxe alone or with other hypoglycemic agents, while in control group 906 patients received placebo or other hypoglycemic agents. In the overall analysis, PEG-Loxe significantly reduced the levels of glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), 2-h postprandial blood glucose (2-h PBG), BMI, and BW compared with control group. However, it had no obvious effect on total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), systolic blood pressure (SBP), and diastolic blood pressure (DBP).
Conclusion: PEG-Loxe has better hypoglycemic effects compared with placebo in patients with T2DM, but could not significantly improved TG, LDL-C, HDL-C, SBP, and DBP. And the combination of conventional hypoglycemic drugs (CHD) and PEG-Loxe could more effectively improve the levels of HbA1c, FPG, 2-h PBG, TC, TG, BMI, and BW compared with CHD in T2DM patients.
Systematic Review Registration:www.inplasy.com, identifier INPLASY202350106

目的：已有研究证实，聚乙二醇洛塞那肽（polyethylene glycol loxenatide，PEG-Loxe）对2型糖尿病（type 2 diabetes mellitus，T2DM）患者的血糖与体重控制具有显著效果，但在改善血脂谱（blood lipid profiles，BLP）与血压（blood pressure，BP）方面仍存在一定争议，尚需更多证据验证其相关作用。为此，本研究旨在全面评估聚乙二醇洛塞那肽对2型糖尿病患者血糖（blood glucose，BG）、血脂谱、血压、体重指数（body mass index，BMI）及体重（body weight，BW）的改善效果，为临床实践提供参考依据。
方法：通过检索PubMed、考克兰图书馆（Cochrane Library）、Embase、Medline、Scopus、Web of Science、中国知网（China National Knowledge Infrastructure）、中国科学期刊数据库（China Scientific Journal）、万方数据（Wanfang Data）及中国生物医学文献数据库（SinoMed），筛选聚乙二醇洛塞那肽治疗2型糖尿病的随机对照试验（randomized controlled trials，RCT）。结局指标涵盖血糖、血脂谱、血压、体重指数及体重。采用RevMan 5.3软件进行数据分析。
结果：共纳入18项试验，涉及2166例患者。试验组1260例患者接受聚乙二醇洛塞那肽单药或联合其他降糖药物治疗，对照组906例患者接受安慰剂或其他降糖药物治疗。整体分析显示，与对照组相比，聚乙二醇洛塞那肽可显著降低糖化血红蛋白（glycosylated hemoglobin，HbA1c）、空腹血浆葡萄糖（fasting plasma glucose，FPG）、餐后2小时血糖（2-h postprandial blood glucose，2-h PBG）、体重指数及体重水平。但该药物对总胆固醇（total cholesterol，TC）、甘油三酯（triglycerides，TG）、低密度脂蛋白胆固醇（low-density lipoprotein cholesterol，LDL-C）、高密度脂蛋白胆固醇（high-density lipoprotein cholesterol，HDL-C）、收缩压（systolic blood pressure，SBP）及舒张压（diastolic blood pressure，DBP）无明显改善作用。
结论：与安慰剂相比，聚乙二醇洛塞那肽对2型糖尿病患者具有更优的降糖效果，但无法显著改善甘油三酯、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、收缩压及舒张压。此外，与单纯使用常规降糖药物（conventional hypoglycemic drugs，CHD）相比，常规降糖药物联合聚乙二醇洛塞那肽可更有效地改善2型糖尿病患者的糖化血红蛋白、空腹血浆葡萄糖、餐后2小时血糖、总胆固醇、甘油三酯、体重指数及体重水平。
系统评价注册：www.inplasy.com，编号INPLASY202350106